Adding to HIV Prevention Options in the Asia-Pacific Region

Lenacapavir (LEN) is an antiretroviral that can be used as a long-acting injectable medicine for both treatment and prevention of HIV in adults and adolescents. Although the drug is approved for use in multiple countries, access remains severely limited in the Asia-Pacific due to a lack of regulatory applications to facilitate marketing and because drug purchasing programs sponsored by international agencies have not included many countries in the region.

amfAR’s TREAT Asia program has prepared a summary on the basics of LEN as a PrEP option.

Read the Snapshot here.